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Objectives The aim of the study was to determine whether staging
primary ovarian cancer using 3.0 Tesla (3T) magnetic resonance
imaging (MRI) is comparable to surgical staging of the disease.
Design A retrospective study consisting of a search of the
pathology database to identify women with ovarian pathology
from May 2004 to January 2007.
Setting All women treated for suspected ovarian cancer in our
cancer centre region.
Sample All women suspected of ovarian pathology who underwent
3T MRI prior to primary surgical intervention between May 2004
and January 2007.
Methods All women found to have ovarian pathology, both
benign and malignant, were then cross checked with the magnetic
resonance (MR) database to identify those who had undergone 3T
MRI prior to surgery. The resulting group of women underwent
comparison of the MR, surgical and histopathological findings for
each individual including diagnosis of benign or malignant disease
and International Federation of Gynecology and Obstetrics (FIGO)
staging where appropriate.
Main outcome measures Comparisons were made between the
staging accuracy of 3T MRI and surgical staging compared with
histopathological findings and FIGO stage using weighted kappa.
Sensitivity, specificity and accuracy were calculated for diagnosing
malignant ovarian disease with 3T MRI.
Results A total of 191 women identified as having ovarian
pathology underwent imaging with 3T MR and primary surgical
intervention. In 19 of these women, the ovarian disease was an
incidental finding. The group for which staging methods were
compared consisted of 77 women of primary ovarian malignancy
(20 of whom had borderline tumours). 3T MRI was able to detect
ovarian malignancy with a sensitivity of 92% and a specificity of
76%. The overall accuracy in detecting malignancy with 3T MRI
was 84%, with a positive predictive value of 80% and negative
predictive value of 90%. Statistical analysis of the two methods of
staging using weighted kappa, gave a K value of 0.926 (SE ±0.121)
for surgical staging and 0.866 (SE ±0.119) for MR staging. A
further analysis of the staging data for ovarian cancers alone,
excluding borderline tumours resulted in a K value of 0.931
(SE ±0.136) for histopathological staging versus MR staging and
0.958 (±0.140) for histopathological stage versus surgical staging.
Conclusion Our study has shown that MRI can achieve staging of
ovarian cancer comparable with the accuracy seen with surgical
staging. No previous studies comparing different modalities have
used the higher field strength 3T MRI. In addition, all other
studies comparing radiological assessment of ovarian cancer have
grouped the stages into I, II, III and IV rather than the more
clinically appropriate a, b and c subgroups.
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Introduction
Ovarian cancer is the fifth most common malignancy affect-
ing women, with nearly 7000 women diagnosed with ovarian
cancer each year in the UK. It continues to have a poor prog-
nosis resulting in 4500 deaths from the disease annually, mak-
ing it the most common cause of gynaecological cancer death.
It tends to affect older women, with half of them occurring
over the age of 65 years. Data from the International Feder-
ation of Gynaecology and Obstetrics (FIGO) quotes 5-year
overall survival rate as increasing from 27% in the 1960s to
42% in the 1990s. However, because of its surreptitious
nature, 75% of women have the disease extending beyond
the pelvis (stages III and IV) at the time of presentation.1
Although overall survival rates have improved, the late pre-
sentation of the disease means it continues to have a poor
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prognosis in the majority of women with only 25% 5-year
survival for advanced disease.2 Improvements in imaging
techniques have allowed characterisation of ovarian masses
and identification of metastatic disease resulting in better man-
agement of women undergoing treatment. This has reduced
the incidence of unnecessary surgery in unsuitable women. For
example, detection of the presence of bulky disease in the upper
abdomen at such sites as the porta hepatis, gastrohepatic
ligament, lesser sac, liver and lymphadenopathy above the renal
hilum makes the possibility of optimal debulking unlikely
(Figure 1). Instead, those women with advanced disease and
who are deemed inoperable receive chemotherapy prior to
surgery, some avoiding surgery altogether.
The usual modalities for imaging of the female pelvis are
ultrasound, Doppler ultrasound, computed tomography (CT)
and magnetic resonance imaging (MRI). All these methods
have been used extensively and are widely reported in the
literature, with CT and MRI have accuracies ranging from
60 to 90% for diagnosis and staging of ovarian malig-
nancy.3–10 The overall findings indicate that MRI is superior
to Doppler ultrasound and CT in determining malignancy,
but there appears to be no difference in the accuracy of CT
and MRI in staging the disease.11,12 MRI is cost-effective and
reliable when the results of ultrasound evaluation are not
clear.13–15 CT is usually not recommended in the evaluation
of adnexal masses because of poor soft tissue discrimination
and the hazards of ionising radiation. MRI is often very help-
ful in characterising adnexal masses as the signal intensity (SI)
and morphological appearance of the lesion reflect the under-
lying pathology. For example, benign endometrial cysts have
a high SI (appear ‘bright’) on T1-weighted images and a low
SI (appear ‘dark’) on T2-weighted images, whereas serous
malignancies often contain vegetations that are of low SI on
T2-weighted images (Figure 2) and typically enhance follow-
ing contrast administration.
The current FIGO guidelines recommend exploratory lap-
arotomy as the gold standard for all women suspected of
having ovarian cancer. This should provide tissue for histo-
logical assessment to confirm the diagnosis, allow maximal
debulking of tumour volume and provide information on the
extent of spread of the disease for staging. Such use of surgery
has meant that traditionally imaging has played a limited role
in the initial management of these women. However, laparot-
omy may not detect all deposits, carries its own risks and may
delay further treatment such as chemotherapy. Thus, imaging
is required preoperatively to determine sites of disease and
hence areas in need of biopsy. In addition, women with
advanced disease can be referred to a Cancer Centre and
Gynaecological Oncologist, as specialist treatment produces
a significant improvement in survival.16 Observational studies
have provided convincing evidence to support this statement,
with data suggesting that 3 years after treatment by a specialist
gynaecologist, a woman’s chance of dying is 25% lower than
if treated by a general gynaecologist and 33% lower than if
treated by a general surgeon.17
The correct staging of ovarian cancer is essential, particu-
larly for those with apparent early stage disease. Numerous
studies have shown that understaging of ovarian cancer is
common and as many as 30–40% women who were thought
to have early disease on initial operative findings were found
to have a more advanced stage of the disease on re-investigation
at tertiary referral centres.18,19 As a consequence of these
reports, it has been advised that ovarian cancer should be
Figure 1. (A) Abdominal image showing small tumour deposit in falciform ligament. (B) Abdominal image showing tumour deposit on the right
(a) hemi-diaphragm and (b) omental disease.
Figure 2. (A) Axial 3T MR image of bilateral serous cystadenocarcinomas
showing complex cyst structure in a patient with FIGO stage IIIc disease.
(B) Sagittal 3T MR image of a patient with FIGO stage IIIc disease
showing ascites, omental cake and ovarian masses.
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diagnosed and staged surgically with laparotomy aiming for
complete resection of the tumour or at the very least, optimal
debulking with individual tumour deposits measuring no
more than 1.2–2.0 cm in size.20–22 One benefit of primary
surgical intervention is that it provides tissue for histological
diagnosis.
In those women who are deemed to be inoperable, that is
optimal debulking is unlikely to be achieved, then neoadju-
vant chemotherapy may be commenced followed by interval
debulking surgery. Due to the continued controversy about
the use of debulking surgery in the management of advanced
ovarian cancer, a current Medical Research Council study,
‘CHORUS’ is continuing. This is designed in part to deter-
mine if chemotherapy or upfront surgery is the better treat-
ment in women with advanced (stage III or IV) ovarian
cancer (http://www.ctu.mrc.ac.uk/studies/CHORUS.asp).
In a paper by Spencer published in 2005, CT is quoted as
being the mainstay of imaging of women believed to have
ovarian cancer based on a combination of its efficacy and
availability.23 It was also felt that MRI should be used as
a ‘problem solving’ investigation for the indeterminate
adnexal mass rather than a preoperative staging tool due to
its limited availability in most hospitals.
We would like to challenge the idea that MRI cannot be
used to stage ovarian cancer, particularly since the introduc-
tion of 3.0 Tesla (3T) MRI, which produces better image
quality compared with the lower field strength 1.5T magnetic
resonance (MR) machines due to the increased signal-to-
noise ratio (SNR).
Patients and methods
A search of the histopathology database (LabCentre, Clinicom
CliniSys) was performed for the period of May 2004 to Jan-
uary 2007 to identify all women reported as having ovarian
pathology, both benign and malignant cases as determined by
SNOMED (Systemized Nomenclature of Medicine) coding.
This time period coincided with the introduction of the
3.0 Tesla Signa HDX whole body MR scanner (GE Medical
Systems, Milwaukee, WI, USA). Overall, 528 women were
recorded as having ovarian pathology, some of whom were
incidental findings of ovarian tumours, metastases and recur-
rences of previously diagnosed malignancy. The records of all
women diagnosed with ovarian pathology in whom 3T MRI
had been performed prior to surgery were then reviewed.
Women with a diagnosis of ovarian cancer, but who had
chemotherapy rather than primary debulking surgery were
excluded, as were women who had alternative imaging prior
to surgery such as ultrasound scan, 1.5T MRI or CT imaging.
To avoid bias, the staging was determined from the initial
MRI report and the source images were not reviewed for the
purpose of this study. When not already stated in the text of
the MRI report, the staging was deduced from the MRI
findings as described in the text, according to the FIGO
classification of ovarian cancer (Table 1). Images were
acquired using a Signa HDX 3T MR scanner with an
eight-channel pelvic phased array coil (GE Healthcare). A
dielectric pad consisting of a 1.6 l of an aqueous solution of
50 g of manganese sodium was used for 3T MRI to prevent
any signal inhomogeneity.24 In cases where the lesion was
predominantly cystic, gadodiamide contrast agent (Omni-
scan; Amersham Health AS, Oslo, Norway) was given intra-
venously at a dosage of 0.1 mmol/kg body weight to aid
visualisation of the internal architecture. All women received
20 mg of hyoscine butylbromide (Buscopan; Boehringer
Ingelheim Ltd, Bracknell, UK) unless contraindicated, to
reduce peristalsis-induced image blurring. T2-weighted fast
spin echo (FSE) images were acquired (repetition time [TR]
2800 ms/echo time [TE] 105 ms) through sagittal, axial and
oblique planes in the pelvis. When using contrast T1-
weighted spin echo, images were acquired both pre- and
postcontrast. Abdominal imaging was acquired using signal
averaged fast recovery FSE with a TR of 5000 ms and TE of
82.4 ms. Breath hold axial images were acquired as single
shot FSE with TR of 1600 ms and TE of 80.3 ms. The same
Table 1. FIGO Staging of Ovarian Cancer (1986)
Stage I—tumour limited to one or both ovaries
IA—involves one ovary; capsule intact; no tumour on ovarian
surface; no malignant cells in ascites or peritoneal washings
IB—involves both ovaries; capsule intact; no tumour on ovarian
surface; negative washings
IC—tumour limited to ovaries with any of the following: capsule
ruptured, tumour on ovarian surface, positive washings
Stage II—tumour involving one or both ovaries with pelvic
extension or implants
IIA—extension or implants onto uterus or fallopian tube;
negative washings
IIB—extension or implants onto other pelvic structures; negative
washings
IIC—pelvic extension or implants with positive peritoneal
washings
Stage III—tumour involving one or both ovaries with
microscopic peritoneal implants outside of the pelvis; or
limited to the pelvis with extension to the small bowel
or omentum
IIIA—microscopic peritoneal metastases beyond pelvis
IIIB—macroscopic peritoneal metastases beyond pelvis less than
2 cm in size
IIIC—peritoneal metastases beyond pelvis .2 cm or lymph node
metastases
Stage IV—tumour involving one or both ovaries with
distant metastases; if a pleural effusion is present there
must be positive cytology for it to be classed as
stage IV disease
Para-aortic lymph node metastases are considered regional
lymph nodes (stage IIIC)
Booth et al.
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consultant radiologist reported all the cases, thus avoiding
interobserver bias.
Reporting of histopathological specimens was carried out
by one of the two consultant histopathologists with particular
interest in gynaecology. In order that false-negative and false-
positive results are not overlooked, all histopathology reports
were reviewed for women with ovarian pathology who had
undergone 3T MRI prior to surgery. For the few women
where FIGO staging was not already stated, staging was deter-
mined from the text of the pathology report according to
FIGO recommendations (Table 1).
Those women identified from 3T MRI and histopathology
as being suspected to have or having ovarian malignancy all
underwent review of the surgical findings as recorded in the
patient’s case notes. The surgical staging was then compared
with both MR and histopathological staging of disease. All
women found to have ovarian malignancy who had also
undergone 3T MRI were operated on by one of the two expe-
rienced gynaecologists with a special interest in gynaecolog-
ical oncology.
Results
Over the time period, 191 women identified as having ovarian
pathology underwent 3T MRI. Of the 191 women, 172 had
ovarian disease as their primary diagnosis on histology. There
were a further 19 women in whom the main diagnosis was
uterine pathology, with incidental findings of ovarian disease
(13 with endometrial adenocarcinoma, 3 with uterine sar-
coma and 3 with benign leiomyoma).
In the case of both benign and malignant ovarian disease
occurring in the same woman, the malignant disease was
noted as the primary diagnosis.
Primary ovarian malignancy was diagnosed in 77 women
(20 of whom had borderline malignancies). These individuals
had undergone primary debulking surgery and subsequent
histopathological staging and formed the study group for
whom staging data was calculated. There were a further 18
women in whom malignancy was suspected or could not be
excluded on MRI, but were found to have benign disease on
histology. Of these 18 women of suspected ovarian cancer, 5
were thought to have borderline disease on MRI, 2 of which
were surgically staged as Ic disease. On histopathological ex-
amination, the majority of these tumours were either muci-
nous cystadenomas or serous adenofibromas with a further
two cases of ovarian torsion.
There were six women who were not thought to have
malignancy on MRI, but were subsequently found to have
ovarian tumours on histopathological examination (false neg-
ative). Five of these were stage Ia borderline tumours with
a single case of squamous cell cancer arising in a pre-existing
mature cystic teratoma.
Metastatic ovarian disease was found in further seven
women, and in one woman there was an extragastrointestinal
stromal tumour arising in the broad ligament. This was not
included in the results due to its rare nature and there being
no recognised staging for this particular tumour. There was
also a case of a gonadoblastoma arising in a woman with
androgen insensitivity syndrome (testicular feminisation),
which was excluded from the final data. In those women
found to have benign disease, there were three women with
ovarian torsion, 22 benign teratomas and a further 52 women
with benign ovarian tumours, predominantly cystadenoma
and fibroma. A summary of the gynaecological pathologies
can be found in Table 2.
Themean age of women undergoing surgery for a suspected
ovarian malignancy was 59 years, with a range of 27–90 years.
The mean age of those diagnosed with ovarian cancer was 56
years (range 26–89) with a slightly higher mean of 65 years
(range 35–90) for those women found to have benign disease
following surgery.
The ability to detect ovarian malignancy with 3T MRI was
comparable with other studies, with a sensitivity of 92% and
a specificity of 76%. The overall accuracy in detecting malig-
nancy with 3T MRI was 84%, with a positive predictive value
was 80% and negative predictive value of 90%.
Direct comparisons of surgical, histopathological and MR
staging was achieved by allotting an incremental score for
Table 2. Summary of gynaecological pathologies, both benign and malignant, in whom 3T MRI was performed
Ovarian neoplasms
Total ovarian malignancies Primary malignancy Borderline malignancy Metastatic Recurrence Secondary debulking
98 57 20 7 3 11
Total benign Dermoid Cystadenoma Fibroma Other Torsion
74 22 37 10 5 3
Uterine neoplasms
Total Adenocarcinoma Sarcoma Leiomyoma
19 13 3 3
3T MRI staging of ovarian cancer
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each of the stages of disease, thus producing linear data
(Table 3). This was then analysed using weighted kappa sta-
tistical test.
Weighted kappa is a test for interobserver agreement, in
which a K value of 1 amounts to perfect agreement, and value
of 0 is complete disagreement. The weighting of the differ-
ences allows for the fact that there are degrees of disagree-
ment between observers. The K value is interpreted as
follows:25
Value of K Strength of agreement
,0.20 Poor
0.21–0.40 Fair
0.41–0.60 Moderate
0.61–0.80 Good
0.81–1.00 Very good
Statistical analysis of the two methods of staging when
compared with the stage obtained by histopathological exam-
ination using weighted kappa, gave a K value of 0.926 (SE
±0.121) for surgical staging and 0.866 (SE ±0.119) for MR
staging (Tables 4 and 5). Comparison of the MR stage and
surgical stage with the histopathological stage revealed there
was no significant difference between the two. Due to the high
proportion of borderline tumours in our final data, we per-
formed a further analysis of the staging data for ovarian cancers
alone after removing the borderline tumours. This resulted in
a K value of 0.931 (SE ±0.136) for histopathological staging
versus MR staging (Table 6) and a K value of 0.958 (±0.140)
for histopathological stage versus surgical staging (Table 7).
Discussion
3T high-field MRI has been used in a number of areas with
particular applications in neurology, with other applications
for whole body imaging also under investigation.26–32 MRI at
this field strength allows us to double the SNR, which is
fundamental in the quality of the final image. The signal
determines the brightness of each image pixel and is propor-
tional to the radio frequency (RF) emitted by the tissue. The
noise is due to random RF emissions, mainly from the
patient. In simple terms, 3T MRI has twice the strength of
1.5T MRI and provides more information about structure
and function of tissues, in half the time of the 1.5T machines.
A review of the literature revealed that previously published
papers comparing surgical staging with staging determined by
MRI have analysed the data in the broad categories of stages
I, II, III and IV diseases. We have compared the different
Table 3. Showing the incremental scores assigned to each FIGO
stage for ovarian cancer
FIGO stage Assigned score
Ia 1
Ib 2
Ic 3
IIa 4
IIb 5
IIc 6
IIIa 7
IIIb 8
IIIc 9
IV 10
Table 4. Weighted kappa table for histopathological stage versus
MRI stage
Observer A (histopathological stage) %
Observer B
(MRI stage)
1 2 3 4 5 6 7 8 9
1 11 0 5 1 1 1 0 0 0 26.8
2 0 1 1 0 0 0 0 0 0 2.8
3 5 0 11 0 0 1 0 0 0 23.9
4 0 0 0 1 0 0 0 0 0 1.4
5 0 0 0 1 1 1 1 0 0 5.6
6 1 0 2 0 0 1 1 1 1 9.9
7 0 0 0 0 0 1 0 0 0 1.4
8 0 0 0 0 0 0 0 0 1 1.4
9 0 0 0 0 1 0 0 3 15 26.8
% 23.9 1.4 26.8 4.2 4.2 7.0 2.8 5.6 23.9
Weighted kappa 5 0.866; standard error (Kw# 5 0) 5 0.119.
Table 5. Weighted kappa table for histopathological stage versus
surgical stage
Observer A (histopathological stage) %
Observer B
(surgical stage)
1 2 3 4 5 6 7 8 9
1 15 0 2 0 0 0 0 0 0 25.0
2 1 1 0 0 0 0 0 0 0 2.9
3 0 0 14 0 1 0 0 0 0 22.1
4 0 0 0 2 0 0 0 0 0 2.9
5 0 0 0 1 0 3 0 1 0 7.4
6 0 0 1 0 1 2 0 0 0 5.9
7 1 0 0 0 0 0 1 0 1 4.4
8 0 0 0 0 0 0 1 1 2 5.9
9 0 0 0 0 1 0 0 2 13 23.5
% 25.0 1.5 25.0 4.4 4.4 7.4 2.9 5.9 23.5
Weighted kappa 5 0.926; standard error (Kw# 5 0) 5 0.121.
Booth et al.
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modalities of staging like-for-like, using the full FIGO classi-
fication, that is stage Ia, b and c, stage IIa, b and c, stage IIIa,
b and c, a situation more relevant to the clinical setting.
Whichever method is used, the correct initial diagnosis
and staging of ovarian cancer is important in determining
appropriate referral and treatment to optimise survival.33
Thus, accurate preoperative staging with 3T MRI and sub-
sequent multidisciplinary discussion may prevent inappro-
priate and suboptimal surgery such that tumours deemed
inoperable at presentation may be treated initially with che-
motherapy followed by interval debulking surgery. Unfortu-
nately, less than half of the women with ovarian cancer are
treated by gynaecological oncologists. A recent review of
imaging of ovarian cancer quoted long acquisition times as
another reason to use CT instead of MR; however, our
acquisition time for routine MRI of both pelvis and abdo-
men is 45 minutes in total.
Our results show that it is possible to use 3T MRI not only
in the diagnosis of ovarian malignancy but also to stage the
disease, achieving results comparable with those seen with
surgical staging. However, as with all imaging modalities,
there will be both false-positive and false-negative results
especially with regard to the microscopic disease often asso-
ciated with borderline malignancies. The borderline group of
malignancies is particularly difficult to diagnose without his-
topathological assessment and even then can exhibit only very
subtle cellular changes amounting to no more than slight cyst
wall thickening (Figure 3). Of the six women in whom malig-
nancy was not suspected, five were borderline tumours exhib-
iting no obvious stigmata of malignancy on macroscopic
examination (e.g. vegetations on the capsular surface) with
only microscopic areas of disease found on further examina-
tion. All were staged as Ia tumours. Interestingly, of the 13
women with borderline tumours that were identified as sus-
picious of malignancy on MR examination, over half were
stated as being likely borderline tumours in the MR report,
the remainder were considered to be stage I cystadenomas.
Such subtleties of tumour characterisation are only possible
because of the improved image quality obtained with 3T MR
techniques, allowing better visualisation of the cyst wall and
abnormal areas associated with it. However, this does mean
that subtle changes in benign cysts may be construed as sus-
picious on MR investigation, thus raising the possibility of
malignancy. It is important to consider the clinical picture
Table 6. Weighted kappa table for histopathological stage versus
MRI stage with borderline tumour data removed
Observer A (histopathological stage) %
Observer B
(MRI stage)
1 2 3 4 5 6 7 8 9
1 9 0 4 0 1 0 0 0 0 25.9
2 0 1 1 0 0 0 0 0 0 3.7
3 4 0 10 0 0 0 0 0 0 25.9
4 0 0 0 1 0 0 0 0 0 1.9
5 0 0 0 1 0 2 0 0 0 5.6
6 0 0 0 0 0 0 0 1 0 1.9
7 0 0 0 0 0 1 0 0 0 1.9
8 0 0 0 0 0 0 0 0 1 1.9
9 0 0 0 0 1 0 0 3 13 31.5
% 24.1 1.9 27.8 3.7 3.7 5.6 0.0 7.4 25.9
Weighted kappa 5 0.931; standard error (Kw# 5 0) 5 0.136.
Table 7. Weighted kappa table for histopathological stage versus
surgical stage with borderline tumour data removed
Observer A (histopathological stage) %
Observer B
(surgical stage)
1 2 3 4 5 6 7 8 9
1 12 0 1 0 0 0 0 0 0 25.5
2 1 1 0 0 0 0 0 0 0 3.9
3 0 0 12 0 1 0 0 0 0 25.5
4 0 0 0 1 0 0 0 0 0 2.0
5 0 0 0 1 0 1 0 1 0 5.9
6 0 0 0 0 0 2 0 0 0 3.9
7 0 0 0 0 0 0 0 0 1 2.0
8 0 0 0 0 0 0 0 1 1 3.9
9 0 0 0 0 1 0 0 2 11 27.5
% 25.5 2.0 25.5 3.9 3.9 5.9 0.0 7.8 25.5
Weighted kappa 5 0.958; standard error (Kw’ 5 0) 5 0.140. Figure 3. Oblique 3T MR image of a borderline ovarian malignancy
showing details of subcapsular tumour deposits.
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and tumour markers (if available) when interpreting these
images. Nevertheless, if malignancy cannot be excluded on
MR investigation, it should be treated as such until proven
otherwise. This may lead to an overtreatment of some indi-
viduals who are later found to have benign disease but ensures
that as manywomen as possible are treated by the appropriate
specialist surgeon. In our study, the number of false-positive
cases was comparable to similar studies, which employed
other methods of imaging and assessment in terms of their
sensitivity, specificity, positive and negative predictive values.
The 18 women in whom malignancy was suspected or could
not be excluded and were later found to be benign were
mainly serous or mucinous cystadenomatous lesions.
Although the numbers within this study are small, the
results are positive. The K values obtained from our data
including and excluding the group of borderline tumours
show very good levels of agreement. The continued growth
in the use of 3T MRI for the staging of ovarian cancer should
be pursued. Future considerations to improve the technique
include the use of 16- or 32-channel phased array coils.
Phased array coils are used where possible to improve the
signal-to-noise levels and hence produce clearer MR images.
We currently use an eight-channel phased array coil in clinical
practice, but we may wish to consider using 16- or 32-channel
phased array coils to improve image quality and staging accu-
racy. In addition, further detail of pelvic and abdominal
disease may be achieved with the routine use of ultrathin
three-dimensional (3D) sequences enhanced with intrave-
nous gadodiamide contrast.
The quality of the 3T MRI and the results of this study and
are encouraging, providing clinicians with further evidence of
the merits of this technique. Where facilities allow, we would
encourage the use of 3T MRI in the assessment of cases of
ovarian cancer as it can provide staging accuracy comparable
with that obtained with surgical intervention.
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